Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it

References

• Moshé SL, Perucca E, Ryvlin P, et al. Epilepsy: new advances. Lancet. 2015;385(9971):884‒898.
   PubMed Web of Science ®Google Scholar
• Janmohamed M, Brodie MJ, Kwan P, et al. Pharmacoresistance - epidemiology, mechanisms, and impact on epilepsy treatment. Neuropharmacology. 2020;168:107790.
   PubMed Web of Science ®Google Scholar
• Tang F, Hartz AMS, Bauer B, et al. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol. 2017;8:301.
   PubMed Web of Science ®Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51:1069‒1077.
   Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on?. Seizure. 2000;9(7):464‒468.
   PubMed Web of Science ®Google Scholar
• Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia. 2000;41(11):1364‒1374.
   PubMed Web of Science ®Google Scholar
• Billakota S, Devinsky O, Kim KW, et al. Why we urgently need improved epilepsy therapies for adult patients. Neuropharmacology. 2020;170:107855.
   PubMed Web of Science ®Google Scholar
• Barker-Haliski M, White HS. Validated animal models for antiseizure drug (ASD) discovery: advantages and potential pitfalls in ASD screening. Neuropharmacology. 2020;167:107750.
   PubMed Web of Science ®Google Scholar
• Löscher W. Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies. Epilepsy Res. 2016;126:157‒184.
   PubMed Web of Science ®Google Scholar
• Potschka H. Animal models of drug-resistant epilepsy. Epileptic Disord. 2012;14(3):226–234.
   PubMed Web of Science ®Google Scholar
• Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20(5):359‒368.
   PubMed Web of Science ®Google Scholar
• Riban V, Bouilleret V, Pham-Lê BT, et al. Evolution of hippocampal epileptic activity during the development of hippocampal sclerosis in a mouse model of temporal lobe epilepsy. Neuroscience. 2002;112(1):101–111.
   PubMed Web of Science ®Google Scholar
• Barton ME, Klein BD, Wolf HH, et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47(3):217‒227.
   PubMed Web of Science ®Google Scholar
• Kwan P, Schachter SC, Brodie MJ, et al. Drug-resistant epilepsy. N Engl J Med. 2011;365(10):919‒926.
   PubMed Web of Science ®Google Scholar
• Remy S, Gabriel S, Urban BW, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol. 2003;53(4):469‒479.
   PubMed Web of Science ®Google Scholar
• Remy S, Urban BW, Elger CE, et al. Anticonvulsant pharmacology of voltage-gated Na + channels in hippocampal neurons of control and chronically epileptic rats. Eur J Neurosci. 2003;17(12):2648‒2658.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil M, van Veelen CW, van Rijen PC, et al. Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res. 1998;32(1–2):309‒320.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia. 1999;40(11):1512‒1522.
   PubMed Web of Science ®Google Scholar
• Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia. 2005;46(6):858‒877.
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H, Sisodiya SM, et al., Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3): 606‒638.
   PubMed Web of Science ®Google Scholar
• Ferraro TN, Buono RJ. The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview. Epilepsy Behav. 2005;7(1):18‒36.
   PubMed Web of Science ®Google Scholar
• Kwan P, Poon WS, Ng HK, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics. 2008;18(11):989‒998.
   PubMed Web of Science ®Google Scholar
• Catterall WA, Goldin AL, Waxman SG, et al. International union of pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. 2005;57:397‒409.
   Web of Science ®Google Scholar
• Macdonald RL, Kapur J. Acute cellular alterations in the hippocampus after status epilepticus. Epilepsia. 1999;40(Suppl. s1):S9‒S20.
   Google Scholar
• Jones DM, Esmaeil N, Maren S, et al. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res. 2002;50(3):301‒312.
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Martinian L, Scheffer GL, et al. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol. 2006;32(1):51‒63.
   Web of Science ®Google Scholar
• Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76:22‒76.
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Martinian L, Scheffer GL, et al. Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia. 2003;44(11):1388‒1396.
   Web of Science ®Google Scholar
• Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36(1):1‒6.
   PubMed Web of Science ®Google Scholar
• Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia. 2001;42(12):1501‒1506.
   PubMed Web of Science ®Google Scholar
• Aronica E, Sisodiya SM, Gorter JA, et al. Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev. 2012;64(10):919‒929.
   PubMed Web of Science ®Google Scholar
• Stępień KM, Tomaszewski M, Tomaszewska J, et al. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep. 2012;64(5):1011‒1019.
   Web of Science ®Google Scholar
• Sisodiya SM, Heffernan J, Squier MV, et al. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport. 1999;10(16):3437–3441.
   PubMed Web of Science ®Google Scholar
• Rogawski MA. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia. 2013;54(Suppl 2):33‒40.
   Google Scholar
• Luna-Tortós C, Fedrowitz M, Löscher W, et al. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008;55(8):1364‒1375.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Asselin MC, Liu J, et al. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol. 2013;12(8):777‒7785.
   PubMed Web of Science ®Google Scholar
• Luna-Tortós C, Rambeck B, Jürgens UH, et al. The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins. Pharm Res. 2009;26(11):2464‒2470.
   PubMed Web of Science ®Google Scholar
• Gidal BE. P-glycoprotein expression and pharmacoresistant epilepsy: cause or consequence?. Epilepsy Curr. 2014;14(3):136‒138.
   Web of Science ®Google Scholar
• Lazarowski A, Czornyj L, Lubienieki F, et al. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia. 2007;48(Suppl s5):140‒149.
   PubMedGoogle Scholar
• Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr. 2008;8(5):127‒130.
   PubMedGoogle Scholar
• Löscher W, Brandt C. High seizure frequency prior to antiepileptic treatment is a predictor of pharmacoresistant epilepsy in a rat model of temporal lobe epilepsy. Epilepsia. 2010;51:89‒97.
   PubMed Web of Science ®Google Scholar
• Fang M, Xi ZQ, Wu Y, et al. A new hypothesis of drug refractory epilepsy: neural network hypothesis. Med Hypotheses. 2011;76(6):871‒876.
   Web of Science ®Google Scholar
• Dagenais R, Wilby KJ, Elewa H, et al. Impact of genetic polymorphisms on phenytoin pharmacokinetics and clinical outcomes in the Middle East and North Africa Region. Drugs R D. 2017;17(3):341‒361.
   PubMed Web of Science ®Google Scholar
• Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci U S A. 2005;102(15):5507‒5512.
   PubMed Web of Science ®Google Scholar
• Abe T, Seo T, Ishitsu T, et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br J Clin Pharmacol. 2008;66(2):304‒307.
   PubMed Web of Science ®Google Scholar
• Depondt C. The potential of pharmacogenetics in the treatment of epilepsy. Eur J Paediatr Neurol. 2006;10(2):57‒65.
   PubMed Web of Science ®Google Scholar
• Gambardella A, Labate A, Mumoli L, et al. Role of pharmacogenomics in antiepileptic drug therapy: current status and future perspectives. Curr Pharm Des. 2017;23:5760‒5765.
   PubMed Web of Science ®Google Scholar
• Vezzani A, Aronica E, Mazarati A, et al. Epilepsy and brain inflammation. Exp Neurol. 2013;244:11‒21.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Bernasconi P, Baggi F, et al. Antibodies against GluR3 peptides are not specific for rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol. 2002;131(1–2):179‒185.
   PubMed Web of Science ®Google Scholar
• Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in rasmussen’s encephalitis. Science. 1994;265(5172):648‒651.
   PubMed Web of Science ®Google Scholar
• Choi J, Koh S. Role of brain inflammation in epileptogenesis. Yonsei Med J. 2008;49(1):1‒18.
   Web of Science ®Google Scholar
• Vezzani A, French J, Bartfai T, et al. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31‒40.
   PubMed Web of Science ®Google Scholar
• Vezzani A, Balosso S, Ravizza T, et al. The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun. 2008;22(6):797‒803.
   PubMed Web of Science ®Google Scholar
• Löscher W, Klitgaard H, Twyman RE, et al. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12(10):757‒776.
   PubMed Web of Science ®Google Scholar
• Lee TS, Mane S, Eid T, et al. Gene expression in temporal lobe epilepsy is consistent with increased release of glutamate by astrocytes. Mol Med. 2007;13(1–2):1‒13.
   Web of Science ®Google Scholar
• Foresti ML, Arisi GM, Katki K, et al. Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus. J Neuroinflammation. 2009;6(1):40.
   PubMedGoogle Scholar
• Li R, Ma L, Huang H, et al. Altered expression of CXCL13 and CXCR5 in intractable temporal lobe epilepsy patients and pilocarpine-induced epileptic rats. Neurochem Res. 2017;42(2):526‒540.
   Web of Science ®Google Scholar
• Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 2010;16(4):413‒419.
   PubMed Web of Science ®Google Scholar
• Rawat C, Kukal S, Dahiya UR, et al. Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. J Neuroinflammation. 2019;16(1):197.
   PubMed Web of Science ®Google Scholar
• Tu B, Bazan NG. Hippocampal kindling epileptogenesis upregulates neuronal cyclooxygenase-2 expression in neocortex. Exp Neurol. 2003;179:167‒175.
   PubMed Web of Science ®Google Scholar
• Takemiya T, Suzuki K, Sugiura H, et al. Inducible brain COX-2 facilitates the recurrence of hippocampal seizures in mouse rapid kindling. Prostaglandins Other Lipid Mediat. 2003;71(3–4):205‒216.
   PubMed Web of Science ®Google Scholar
• Potschka H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies?. Epilepsia. 2010;51(8):1333‒1347.
   Web of Science ®Google Scholar
• Fabene PF, Laudanna C, Constantin G, et al. Leukocyte trafficking mechanisms in epilepsy. Mol Immunol. 2013;55(1):100‒104.
   PubMed Web of Science ®Google Scholar
• Fabene PF, Navarro Mora G, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med. 2008;14(12):1377–1383.
   PubMed Web of Science ®Google Scholar
• Terrone G, Balosso S, Pauletti A, et al. Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology. 2020;167:107742.
   PubMed Web of Science ®Google Scholar
• Eastman CL, D’Ambrosio R, Ganesh T, et al. Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury. Neuropharmacology. 2020;172:107907.
   PubMed Web of Science ®Google Scholar
• Aguiar CC, Almeida AB, Araújo PV, et al. Oxidative stress and epilepsy: literature review. Oxid Med Cell Longev. 2012;2012:795259.
   PubMed Web of Science ®Google Scholar
• Sudha K, Rao AV, Rao A, et al. Oxidative stress and antioxidants in epilepsy. Clin Chim Acta. 2001;303(1–2):19‒24.
   PubMed Web of Science ®Google Scholar
• Löscher W, Friedman A. Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence, or both?. Int J Mol Sci. 2020;21(2):591.
   Web of Science ®Google Scholar
• Salar S, Maslarova A, Lippmann K, et al. Blood-brain barrier dysfunction can contribute to pharmacoresistance of seizures. Epilepsia. 2014;55(8):1255‒1263.
   PubMed Web of Science ®Google Scholar
• Crino PB. Mechanistic target of rapamycin (mTOR) signaling in status epilepticus. Epilepsy Behav. 2019;101(Pt B):106550.
   PubMed Web of Science ®Google Scholar
• Zavala-Tecuapetla C, Cuellar-Herrera M, Luna-Munguia H, et al. Insights into potential targets for therapeutic intervention in epilepsy. Int J Mol Sci. 2020;21(22):8573.
   Web of Science ®Google Scholar
• Talos DM, Jacobs LM, Gourmaud S, et al. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy. Ann Neurol. 2018;83(2):311‒327.
   PubMed Web of Science ®Google Scholar
• Ryther RC, Wong M. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Curr Neurol Neurosci Rep. 2012;12(4):410‒418.
   PubMed Web of Science ®Google Scholar
• Almeida SS, Naffah-Mazzacoratti MG, Guimarães PB, et al. Carbamazepine inhibits angiotensin I-converting enzyme, linking it to the pathogenesis of temporal lobe epilepsy. Transl Psychiatry. 2012;2(3):e93.
   PubMedGoogle Scholar
• Pereira MG, Becari C, Oliveira JA, et al. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin Sci (Lond). 2010;119(11):477‒482.
   PubMed Web of Science ®Google Scholar
• Argañaraz GA, Konno AC, Perosa SR, et al. The renin-angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia. 2008;49(8):1348‒1357.
   PubMed Web of Science ®Google Scholar
• Szczurkowska PJ, Polonis K, Becari C, et al. Epilepsy and hypertension: the possible link for SUDEP?. Cardiol J. 2019 Sep 30. DOI:https://doi.org/10.5603/CJ.a2019.0095.
   Google Scholar
• Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat. 2016;12:2605‒2616.
   PubMed Web of Science ®Google Scholar
• Keezer MR, Sisodiya SM, Sander JW, et al. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15(1):106‒115.
   Web of Science ®Google Scholar
• Galovic M, Ferreira-Atuesta C, Abraira L, et al. Seizures and epilepsy after stroke: epidemiology, biomarkers and management. Drugs Aging. 2021 Feb 23;(4). DOI: https://doi.org/10.1007/s40266-021-00837-7.
   Google Scholar
• Samanen J. Chapter 5 - Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics. In: Ganellin R, Jefferis SR, editors. Introduction to Biological and Small Molecule Drug Research and Development. Elsevier; Amsterdam, 2013. p. 161–203.
   Google Scholar
• Greco M, Varriale G, Coppola G, et al. Investigational small molecules in phase II clinical trials for the treatment of epilepsy. Expert Opin Investig Drugs. 2018;27(12):971‒979.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: a clinician’s overview. CNS Drugs. 2017;31(2):135‒147.
   Web of Science ®Google Scholar
• Smith M, Wilcox KS, White HS, et al. Discovery of antiepileptic drugs. Neurotherapeutics. 2007;4(1):12‒17.
   PubMed Web of Science ®Google Scholar
• Wilcox KS, West PJ, Metcalf CS, et al. The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy. Neuropharmacology. 2020;166:107811.
   PubMed Web of Science ®Google Scholar
• Metcalf CS, West PJ, Thomson KE, et al. Development and pharmacologic characterization of the rat 6 Hz model of partial seizures. Epilepsia. 2017;58(6):1073‒1084.
   Web of Science ®Google Scholar
• Schmidt D, Löscher W. New developments in antiepileptic drug resistance: an integrative view. Epilepsy Curr. 2009;9(2):47‒52.
   PubMed Web of Science ®Google Scholar
• van Vliet EA, van Schaik R, Edelbroek PM, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia. 2006;47(4):672‒680.
   PubMed Web of Science ®Google Scholar
• Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006;15(6):637‒647.
   PubMed Web of Science ®Google Scholar
• Perucca E, French J, Bialer M, et al. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6(9):793‒804.
   PubMed Web of Science ®Google Scholar
• Łukawski K, Gryta P, Łuszczki J, et al. Exploring the latest avenues for antiepileptic drug discovery and development. Expert Opin Drug Discov. 2016;11(4):369‒382.
   PubMed Web of Science ®Google Scholar
• Vezzani A, Balosso S, Ravizza T, et al. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat Rev Neurol. 2019;15(8):459‒472.
   PubMed Web of Science ®Google Scholar
• Yu N, Liu H, Di Q, et al. Modulation of immunity and the inflammatory response: a new arget for treating drug-resistant epilepsy. Curr Neuropharmacol. 2013;11:114‒127.
   PubMed Web of Science ®Google Scholar
• Cardenas-Rodriguez N, Huerta-Gertrudis B, Rivera-Espinosa L, et al. Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models. Int J Mol Sci. 2013;14(1):1455‒1476.
   Web of Science ®Google Scholar
• Griffith JL, Wong M. The mTOR pathway in treatment of epilepsy: a clinical update. Future Neurol. 2018;13(2):49‒58.
   PubMed Web of Science ®Google Scholar
• Gomes KP, Braga PPP, De Lima CQ, et al. Antiepileptic effects of long-term intracerebroventricular infusion of angiotensin-(1-7) in an animal model of temporal lobe epilepsy. Clin Sci (Lond). 2020;134(17):2263‒2277.
   PubMed Web of Science ®Google Scholar
• Bar-Klein G, Cacheaux LP, Kamintsky L, et al. Losartan prevents acquired epilepsy via TGF-β signaling suppression. Ann Neurol. 2014;75(6):864‒875.
   PubMed Web of Science ®Google Scholar
• Helbig I, Ellis CA. Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers. Neuropharmacology. 2020;172:107970.
   PubMed Web of Science ®Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov. 2010;9(1):68‒82.
   PubMed Web of Science ®Google Scholar
• Łukawski K, Czuczwar SJ. Developing precision treatments for epilepsy using patient and animal models. Expert Rev Neurother. 2020;29:1‒10.
   Google Scholar
• French JA, Faught E. Rational polytherapy. Epilepsia. 2009;50(Suppl 8):63–68.
   PubMed Web of Science ®Google Scholar
• Holmes M, Flaminio Z, Vardhan M, et al. Cross talk between drug-resistant epilepsy and the gut microbiome. Epilepsia. 2020;61(12):2619‒2628.
   Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother. 2006;6(3):397‒406.
   PubMedGoogle Scholar
• Vaccarezza MM, Silva WH. Dietary therapy is not the best option for refractory nonsurgical epilepsy. Epilepsia. 2015;56(9):1330–1334.
   PubMed Web of Science ®Google Scholar
• Lieb A, Qiu Y, Dixon CL, et al. Biochemical autoregulatory gene therapy for focal epilepsy. Nat Med. 2018;24(9):1324‒1329.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs. 2002;16(9):579‒593.
   PubMed Web of Science ®Google Scholar
• Kullmann DM, Schorge S, Walker MC, et al. Gene therapy in epilepsy-is it time for clinical trials?. Nat Rev Neurol. 2014;10(5):300‒304.
   PubMed Web of Science ®Google Scholar
• Doeser A, Dickhof G, Reitze M, et al. Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug. Brain. 2015;138(2):371–387.
   PubMedGoogle Scholar
• Wang J, Chen Y, Wang Q, et al. The effects of lamotrigine and ethosuximide on seizure frequency, neuronal loss, and astrogliosis in a model of temporal-lobe epilepsy. Brain Res. 2019;1712:1–6.
   PubMed Web of Science ®Google Scholar
• Schidlitzki A, Bascuñana P, Srivastava PK, et al. Proof-of-concept that network pharmacology is effective to modify development of acquired temporal lobe epilepsy. Neurobiol Dis. 2020;134:104664.
   PubMed Web of Science ®Google Scholar
• St Louis EK. Truly “Rational” polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol. 2009;7(2):96–105.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on?. Seizure. 2000;9(7):464–468.
   PubMed Web of Science ®Google Scholar
• Jonker DM, Voskuyl RA, Danhof M, et al. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?. Epilepsia. 2007;48(3):412–434.
   PubMed Web of Science ®Google Scholar
• Błaszczyk B, Miziak B, Czuczwar P, et al. A viewpoint on rational and irrational fixed-drug combinations. Expert Rev Clin Pharmacol. 2018;11(8):761–771.
   PubMed Web of Science ®Google Scholar
• Barker-Haliski M, Sills GJ, White HS, et al. What are the arguments for and against rational therapy for epilepsy?. In: Scharfman HE, Buckmaster PS, editors. Issues in clinical epileptology: a view from the bench. Dordrecht: Springer Science; 2014. p. 295–308.
   Google Scholar
• Asadi-Pooya AA, Razavizadegan SM, Abdi-Ardekani A, et al. Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: a pilot study. Epilepsy Behav. 2013;29(1):150‒154.
   Web of Science ®Google Scholar
• Borlot F, Wither RG, Ali A, et al. A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures. Epilepsy Res. 2014;108(9):1642‒1651.
   PubMed Web of Science ®Google Scholar
• Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci. 2002;22(14):5833–5839.
   PubMed Web of Science ®Google Scholar
• Meng T, Xiao D, Muhammed A, et al. Anti-Inflammatory action and mechanisms of resveratrol. Molecules. 2021;26(1):229.
   PubMed Web of Science ®Google Scholar
• Aldini G, Altomare A, Baron G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018;52(7):751–762.
   PubMed Web of Science ®Google Scholar
• Enatsu R, Wylie E, Kotagal P, et al. Surgically proven coexistence of focal and generalized epilepsy: a case report. Epilepsy Behav. 2013;26(1):61–63.
   PubMed Web of Science ®Google Scholar
• Amin U, Benbadis SR. Two epilepsy types (not seizure types) in the same patient: a rare but interesting occurrence. Eur Neurol. 2020;83(1):89–90.
   PubMed Web of Science ®Google Scholar
• Benbadis SR, Tatum WO 4th, Gieron M, et al. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology. 2003;61(12):1793–1795.
   PubMed Web of Science ®Google Scholar